<DOC>
	<DOCNO>NCT00118170</DOCNO>
	<brief_summary>This phase I trial study side effect best dose sorafenib treat patient metastatic unresectable solid tumor , multiple myeloma , non-Hodgkin 's lymphoma without impaired liver kidney function . Sorafenib may stop growth cancer cell block enzymes need cell growth block blood flow cancer . Sorafenib may different effect patient change liver kidney function</brief_summary>
	<brief_title>Sorafenib Treating Patients With Metastatic Unresectable Solid Tumors , Multiple Myeloma , Non-Hodgkin 's Lymphoma With Without Impaired Liver Kidney Function</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To characterize pharmacokinetics BAY 43-9006 patient hepatic renal dysfunction ( part 1 study ) . II . To determine tolerable start dose BAY 43-9006 patient vary degree hepatic renal dysfunction ( part 2 study ) . OUTLINE : This dose-escalation , multicenter study . Patients assign 1 9 treatment cohort accord hepatic renal function . Patients receive oral sorafenib day 1 daily , twice daily , every day begin day 8 continue 3 month . Patients re-evaluated 3 month . Patients respond disease may continue study treatment absence disease progression unacceptable toxicity . Cohorts 3-6 patient ( per treatment cohort ) receive escalate dos sorafenib maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . At least 6 patient treated MTD . PROJECTED ACCRUAL : A total 120 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Immunoblastic</mesh_term>
	<mesh_term>Plasmablastic Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Lymphomatoid Granulomatosis</mesh_term>
	<mesh_term>Lymphoma , Extranodal NK-T-Cell</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Patients must cytologically histologically confirm tumor metastatic unresectable standard curative palliative measure exist longer effective ; Patients solid tumor , multiple myeloma , nonHodgkin 's lymphoma eligible Lesions accurately measure least one dimension ( long diameter record ) ≥ 20 mm conventional technique ≥ 10 mm spiral CT scan All lesion , include small lesion ( long diameter &lt; 20 mm conventional technique &lt; 10 mm spiral CT scan ) truly nonmeasurable lesion ; Lesions consider nonmeasurable include follow : Bone lesion Ascites Pleural/pericardial effusion Lymphangitis cutis/pulmonis Abdominal mass confirm followed imaging technique Cystic lesion ≥ 4 week since major surgery ≥ 4 week since completion radiation chemotherapy except ≥ 6 week nitrosoureas , LPAM mitomycinC ECOG Performance Status 02 Nonpregnant nonnursing effect BAY 439006 fetus/infant unknown ; addition , woman childbearing potential men must agree use appropriate method birth control throughout participation study ; appropriate method birth control include abstinence , oral contraceptive , implantable hormonal contraceptive ( Norplant ) , double barrier method ( diaphragm plus condom ) No patient uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , uncontrolled hypertension , psychiatric illness/social situation would limit compliance study requirement No concomitant medication know cause hepatic renal toxicity , include antiseizure medication , nonsteroidal antiinflammatory agent , steroids No gastrointestinal tract disease result inability take oral medication requirement IV alimentation , prior surgical procedure affect absorption , active peptic ulcer disease No HIVpositive patient receive combination antiretroviral therapy possible pharmacokinetic interaction BAY 439006 ; however , patient HIV+ without AIDS define diagnosis combination antiretroviral therapy eligible No patient evidence biliary renal obstruction ; patient observe least one week treatment ( i.e . stent drain ) biliary renal obstruction ensure organ dysfunction stabilize registration protocol No current treatment investigational agent No evidence bleed diathesis No patient therapeutic anticoagulation ; prophylactic anticoagulation ( i.e. , low dose warfarin ) venous arterial access device allow provided requirement PT , INR PTT meet No treatment cytochrome P450 enzymeinducing antiepileptic drug ( phenytoin , carbamazepine Phenobarbital ) , rifampin St. John 's wort Patients brain metastasis eligible meet follow criterion : Asymptomatic Radiographically stable disease least 2 month Previously receive treatment brain metastasis Not currently receive steroid therapy enzymeinducing anticonvulsant ( e.g . phenytoin , phenobarbital , carbamazepine ) Granulocytes ≥ 1,500/μl Platelet count ≥ 75,000/μl Normal abnormal organ function</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>